Living close to restaurants may not necessarily lead to obesity.

For someone living in close proximity to fast food restaurants, it may be ridiculously difficult to resist their food. On the other hand, someone who lives close to their gym, must be easily able to visit it and lose some weight. We have been living with such notions all our life, but it may not be really true. A new study suggests that living close to fast food joint or gyms has nothing to do with your weight gain or gain loss!

Researchers at the Lund University in Sweden claim there is no correlation between obesity and how close you live to fast food restaurants or gyms. It has come as a shock since many other previous studies from other countries suggested that location and distance of restaurants and gyms from our house may act as major factors in adult obesity.

Kenta Okuyama, PhD student at Center for Primary Health Care Research at Lund University, said, "Our large-scale study in Sweden, using longitudinal national registry data of more than 1,5 million adults, did not find a statistically significant association between these two types of facilities and obesity,"

However, the researchers admitted that the kind of area we live in still plays a role in dictating our overall health, including obesity. For example, urban areas with educated and informed people might be aware of the consequences of obesity and may take preventive measures. While deprived regions with low-income level may suffer from high obesity cases.

"Although reducing fast food outlets or introducing physical activity facilities might in theory promote healthy eating and exercise, it may not be very effective in all countries and regions, because the contexts vary by its culture and lifestyle that may affect how often people utilize these facilities in their daily lives," said Kenta Okuyama.

Read more here:
Weight Loss Or Weight Gain Or Obesity Is Not Affected By Proximity Of Your House To Restaurants Or Gym; Says Study - NDTV Food

Intermittent fasting is based on the idea that you can lose weight if you limit the window of time where you're allowed to eat. This makes it unique from many other diets.

"Intermittent fasting focuses on when a person should eat food, not what type of food he or she eats," says Divya Selvakumar, a registered dietitian, author, and founder of Divine Diets, LLC.

Eating for only a limited window means that you fast for the rest of the time, but are allowed to consume calorie-free beverages like coffee. The purpose of the fast is to kickstart a metabolic state called ketosis. While in ketosis, your body burns fat for fuel instead of sugar.

According to the limited, short-term studies, intermittent fasting does work to help people lose weight in a matter of weeks. However, there are many different approaches to intermittent fasting, so here's a guide for what to know to help you decide which fasting method may be right for you.

The 16:8 approach is possibly the most common method of intermittent fasting. It's sometimes called time-restricted fasting, and there are several slightly different variations.

In the 16:8 version, you fast for 16 hours and limit your eating to an eight-hour window of time during the day.

Most people skip breakfast as part of the 16-hour window, says Selvakumar. So, you might eat between the window from 12 pm to 8 pm, for example.

However, some may choose to skip dinner, instead. For this, you might limit your eating window to between 9 am and 5 pm each day.

According to registered dietitian Natalie Allen, a clinical assistant professor at Missouri State University, most people choose some version of the 16:8, because it's easier to follow than some other versions.

Research suggests that this type of intermittent fasting can help you lose fat and perhaps even improve your cholesterol levels, among other health benefits.

As the name implies, alternate-day intermittent fasting is when you fast or severely restrict your caloric intake every other day.

Allen says that the alternate-day fasting approach is much less popular. Plus, it may be the most challenging type of intermittent fasting to attempt. As a 2017 article in the Annual Review of Nutrition puts it, "[T]his fasting regimen may not be practical because it leads to intense hunger on fasting days."

Another 2017 study in JAMA Internal Medicine found that most of the people who dropped out of an intermittent fasting research study in an attempt to lose weight were the participants who were attempting to do alternate day fasting. Also, it didn't produce greater weight loss or weight maintenance.

"Generally, we don't recommend it," Allen says. "It's hard to not eat for a whole day. I would worry about your blood sugars, your insulin levels, your energy levels, your ability to think. And are you going to be hangry?"

For 5:2 intermittent fasting, you eat normally for five days of the week and drastically reduce your caloric intake for two non-consecutive days. Women restrict themselves to 500 calories, and men to 600 calories on fasting days.

Some people prefer the 5:2 approach. But a 2018 study in The American Journal of Clinical Nutrition found that while this version was effective on the weight loss front, it was not more effective than a continuous calorie restriction approach in which people tried to reduce the number of calories they consumed each day.

The OMAD (one meal a day) diet is where you limit your eating window to just one hour each day and fast for the remaining 23 hours. This is an extreme type of intermittent fasting, and it can be an effective weight-loss strategy for some people.

It can even help to lower some of the risk factors for cardiovascular disease. However, you have to be able to last the entire 23 hours between meals and resist the temptation to overeat during that window, as intense hunger is a common side effect of this method.

Your own tolerance for hunger pangs may guide you in choosing which version of intermittent fasting is best for you. While intermittent fasting is generally safe for most healthy adults, it's not meant for everyone.

"People who are diabetic, pregnant, nursing, athletes, or children: none of those people should be doing intermittent fasting," says Allen. People with eating disorders also should avoid intermittent fasting and restrictive diets, in general.

For the average healthy adult, Allen gives the following advice: "If you want to try it, pick the hours that you want to eat and that you want to fast. Make healthy choices during those times and see if it works for you."

In fact, what you eat when intermittent fasting may even help prevent hunger pains.

Follow this link:
The different types of intermittent fasting and which may be more beneficial to your health - Insider - INSIDER

Vancouver, British Columbia--(Newsfile Corp. - May 21, 2020) - The Yield Growth Corp. (CSE :BOSS) (OTCQB: BOSQF) (FSE: YG3) majority owned subsidiary NeonMind Biosciences Inc. ("NeonMind") has taken further steps towards commencing its clinical studies to confirm that psilocybin (a compound in psychedelic mushrooms) is an effective treatment for food cravings and weight loss. NeonMind has now identified a source of psilocybin in Canada and has identified a laboratory at a University in Canada in which to conduct the studies.

NeonMind Taking Steps to Prove Psilocybin Effective for Weight Loss

To view an enhanced version of this image, please visit:https://orders.newsfilecorp.com/files/6377/56268_PR_WEB_Psilocybin%20Source.jpg

NeonMind previously announced that it had engaged Translational Life Sciences Inc. ("TLS") to conduct the study and that TLS had completed the design of a study to confirm that psilocybin (found in psychedelic mushrooms) is an effective treatment for weight loss and food craving.

TLS has identified a source of synthetically created psilocybin, manufactured by a licensed laboratory, for use in the NeonMind studies. Also, NeonMind has identified a laboratory where the studies can be carried out (the "Lab"). Before the psilocybin can be ordered and before NeonMind can enter into an agreement with the Lab, the Lab must first obtain an exemption from the Canadian Minister of Health pursuant to Subsection 56(1) of the Controlled Drugs and Substances Act, S.C. 1996, c. 19 by the researchers at the Lab to allow them to use psilocybin, a controlled substance, in research studies. NeonMind expects the exemption to be granted within a few months. Researchers at the Lab have previously obtained other exemptions for research involving controlled substances.

"Psilocybin is known to activate serotonin receptors," says Dr. William Panenka, the Director of TLS, "As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings."

TLS has provided an estimate of $250,000 as a budget for the study and an estimated time frame of 6 months to complete the study, with valuable data anticipated to be available within the first few months. TLS estimates that all necessary approvals can be obtained so that the study can commence in the fall of 2020. NeonMind plans to fund the study using previous capital raised and from the proceeds of a planned initial public offering of NeonMind, for which due diligence is currently underway with a Canadian investment dealer.

According to the terms of the TLS engagement, signed on May 6, 2020, NeonMind and TLS agreed to work together to conduct the evaluation of psilocin or psilocybin on cravings, on the metabolism, on food addiction and on glucose and hormone levels. Neon authorized TLS to perform activities required to prepare for and conduct the study and the parties shall work towards entering into a clinical study agreement. NeonMind agreed to pay for all costs related to the study and TLS agreed to arrange for required regulatory exemptions and licenses, and engagement of all necessary parties to conduct the study.

Story continues

According to the World Health Organization, in 2016, more than 1.9 billion adults, 18 years and older, were overweight. The global projected market for weight loss and weight management is estimated at US$245 billion, according to marketsandmarkets. This is over 12x the size of the global anxiety disorder and depression treatment market which is forecast to reach US$18.9 billion by 2026, according to a report by Reports and Data.

About Translational Life Sciences Inc.

TLS is a contract research organization and a life sciences company focused on developing proprietary formulations that contain restricted substances such as psilocybin and cannabis for clinical applications to serve unmet medical needs in the market. The TLS team is composed of physicians and scientists who are recognized thought leaders in the fields of Neurology, Pharmacology, Diabetes, Addiction and Biochemistry and have significant experience in the clinical application of cannabinoid compounds. The founder of TLS, Dr. Panenka, is a dually boarded Neurologist and Psychiatrist and Canadian Institute of Health Research funded academic faculty member at the University of British Columbia. Dr. Panenka did a post doctoral fellowship at UBC and Harvard University, and maintains an internationally recognized research program in brain injury, mental health and addictions.

About NeonMind Biosciences Inc.

NeonMind is dedicated to the enhancement of human life and wellness through the advancement of bioscience to engage the mind to heal the body. It aims to be a leader in the fast-growing functional and adaptogenic foods market, and is engaged in research and the development of products and services using medicinal and psychedelic mushrooms to heal the body through the mind. NeonMind has filed a U.S. provisional patent application to protect the invention that the administration of psilocin and/or psilocybin results in overall weight loss in individuals by reducing food cravings, counteracting compulsive overeating, improving quality of diet, increasing metabolism, treating diabetes, regulating blood glucose and reducing susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus and other illnesses associated with obesity. NeonMind owns 18% of Translational Life Sciences Inc. Yield Growth owns approximately 68% of the issued and outstanding stock of NeonMind.

About The Yield Growth Corp.

The Yield Growth Corp. (CSE: BOSS), (OTCQB: BOSQF) is a phytoceutical and consumer packaged goods company that develops and acquires intellectual property and other assets related to plant-based products and therapeutics, and develops, manufactures, markets, sells and distributes plant-based products that improve lives. It has over 200 proprietary wellness formulas at various stages of commercialization. It is currently launching several hand sanitizer products in response to COVID-19. Its products are sold through e-commerce worldwide and retail stores in 3 countries with distribution agreements in place for 12 more countries. It has 14 patent applications filed in what the Global Wellness Institute reports is a $4.2 trillion-dollar global wellness market. Its majority owned subsidiary NeonMind Biosciences Inc. is launching a line of medicinal mushroom products and is developing intellectual property in the emerging area of psychedelic medicine. The Yield Growth management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, Skechers and Aritzia.

For more information about Yield Growth, visit http://www.yieldgrowth.com or follow @yieldgrowth on Instagram.

Investor Relations Contacts:

Penny White, President & CEO

Kevan Matheson, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677

1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, "forward looking statements") under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies do to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company's products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56268

Continue reading here:
NeonMind Taking Steps to Prove Psilocybin Effective for Weight Loss - Yahoo Finance

Mike Schultz pictured on his Instagram page in February 2020.

Mike Schultz is the San Francisco nurse who lost 50 pounds following a battle with coronavirus. Schultzs side-by-side photos showing the weight loss went viral in May 2020.

In his most recent Facebook post, Schultz shared the news that he had been sent home from the hospital and stopped at McDonalds along the way. Schultz was being treated at New England Sinai Hospital in Stoughton, Massachusetts. Schultz has previously said that he had no underlying health conditions.

Heres what you need to know:

Schultz, 43, posted the photo on May 11. At the time of writing, the picture has received over 18,000 likes. Schultz said in the caption of the photo that he had been sedated for six weeks. He added that due to pneumonia, his lung capacity has been reduced. Schultz spent eight weeks in the hospital, away from family and friends. Schultz concluded the post: Getting stronger everyday and working to increase my lung capacity. Ill get back to where I was in healthier ways this time.maybe even do cardio.

In the space of those six weeks, Schultzs weight went from 190 to 140 pounds, he told BuzzFeed News.

Instagram/Mike SchultzSchultz on May 6.

In a post on May 6, Schultz wrote that he was able to eat and drink what he wanted after passing a medical test. Schultz also paid tribute to his boyfriend, renowned Boston-area DJ J Warren aka Josh Hebblethwaite. Schultz said the couple hadnt seen each other since March 17.

Schultz then took the opportunity to remind everybody, This disease is no joke people. If you think youre too young to get it, think again.

Schultz told Buzzfeed News that after six weeks of being sedated and intubated, he lost his sense of time. Schultz said, I thought only a week had gone by. I was so weak. This was one of the most frustrating parts. I couldnt hold my cellphone; it was so heavy. I couldnt type, because my hands shook so much.

Pink News was the first to report in April 2020 that Schultz was one of the attendees at the Winter Party Festival in Miami Beach who had contracted coronavirus. During his time at the festival, Schultz posted several photos of himself in Miami Beach. In total, the Miami Herald reported at least 38 people contracted coronavirus at Winter Party, and three people died, according to NBC Miami.

Schultz told Buzzfeed News about the feeling around coronavirus during the festival saying, We knew it was out there. There were no real restrictions in place, though. No lockdowns. We just thought, Well, we gotta wash our hands more and be wary of touching our face. Schultz said he and his boyfriend have received negative comments on social media due to their attendance at Winter Party.

On March 10, Schultz traveled to Boston alongside Hebblethwaite following an amazing weekend in Florida, according to Pink News. Hebblethwaite had been a DJ at the event. It was in Boston that Schultz first noticed the symptoms before being hospitalized a few days later.

A GoFundMe page was set up to help Schultz to pay for the medical costs incurred from a two-month stay in the hospital. The most recent update on the page is from Schultz announcing his release from the hospital. Schultz said:

After 57 days in the hospital and rehab unable to see any visitors, Im finally going home!! I plan on continuing my recovering with my guardian angel and boyfriend, Josh, who checked in on my several times a day if not more.

Im am forever thankful for everyones donations, kind words, and prayers. I truly believe they helped me get through this horribly scary ordeal. But first I have to make a stop at McDonalds for a yummy shake.

In a Facebook post following Schultzs release from the hospital, Hebblethwaite said that his boyfriend inspires me with his strength and courage! The couple has been together since the summer of 2019.

Multiple posts on Schultzs Instagram page show him modeling in leather wear. Those posts are accompanied with the hashtag leatherdaddy.

On his Instagram bio, Schultz describes himself as being Made in Detroit. Schultz said that he is a San Francisco-based registered nurse. Schultz goes by the moniker The Bearded Nurse on his profile. He has over 30,000 followers.

READ NEXT: Teenage Porn Star Controversy Rocks California High School

Continue reading here:
Mike Schultz: 5 Fast Facts You Need to Know - Heavy.com